We're creating the world’s first liquid home ownership platform, making it easier to buy, sell and release value.Over the last few decades, property ownership has become progressively more unaffordable, while selling has remained a slow, complicated process.We're introducing new ways to finance purchases and enable more rapid sales online using a single portal, making property ownership far more accessible and flexible.Liqquid (formerly branded as iYield) is currently beta-testing its platform.

Co-founder of Elevate Capital. Elevate builds and operates liquid marketplaces for real estate under the trading name of Liqquid (formerly branded as iYield).In 2015, Elevate built the world's first online marketplace to enable real-time trading of privately-held real estate debt and equity. Following a successful beta launch, crowdfunding the purchase of a number of residential properties across the UK, the company decided to apply its core technology to address the long-standing problems of affordability and liquidity in the real estate sector. It has resulted in a new marketplace, Liqquid, with innovative new home finance products and rapid, guaranteed sale solutions alongside mainstream mortgages.

Co-founded Generis Capital Partners in 2008 to provide venture capital and growth debt financing to private and listed technology companies across Europe. Generis raised €30M across 4 funds based in Paris and closed 10 equity investments / growth debt facilities in 2010, funding companies in healthcare, e-commerce, digital media and information technology sectors in the UK, France, Germany and the Netherlands.

Board member of pharmaceutical development services company Octoplus N.V. (Euronext: Octo.AS). Co-led investment by Innoven Partenaires in December 2004 as part of €18.25M round. Octoplus completed its IPO on Euronext in October 2006 and several private placements during the next 4 years. The company outlicensed its lead product, Locteron, a controlled-release hepatitis C therapeutic in 2008 in a deal worth up to $149M. Remained on the Supervisory Board until May 2010 while at Noble and at Generis Capital Partners.

Responsible for the management of Noble's venture capital activities, including several Venture Capital Trusts, investing in unquoted UK growth companies, and selected listed companies via PIPE transactions (Private Investment in Public Equity). Collaborated with the firm's venture debt group to introduce and review new investment opportunities and enlarge its network of venture capital funds.

Co-led an investment by Innoven Partenaires in CMC, a contract biologics manufacturer, in December 2004 and became a Board Director. Participated in several follow-on financings between 2005 and 2008 (total commitment of €6.4M) during a period of rapid growth for CMC, which successfully acquired Seattle-based ICOS Biologics from Eli Lilly in January 2008. Resigned from Board in February 2008 upon sale of part of Innoven's shareholding to US buyout fund, Monitor Clipper.

Led investment by Innoven Partenaires in BioVex in Devember 2004 and became a Board Observer. Participated in several follow-on investment rounds as the company's lead OncoVex head and neck cancer and melanoma therapeutic advanced successfully through Phase II clinical testing. BioVex relocated to Cambridge, MA, in 2005. Remained a Board Observer until leaving Innoven in June 2007. BioVex was acquired by Amgen in January 2011 in a deal worth up to $1 Billion.

Led a leveraged buyout of Innoven Partenaires, an international venture capital fund based in Paris. Managed 15 FCPI funds (retail, tax-efficient products similar to VCTs), improving the Net Asset Value of the majority of the funds from lower quartile to top decile between 2004 and 2007 (as ranked by Boursorama). Assets under management doubled to >€200M during this period.Involved in the IPOs of 5 of the portfolio companies and several exits, two with tranches sold at in excess of 10x original cost.

Co-led an investment by Innoven Partenaires in December 2005 and became a Board Director. Participated in several follow-on financings. Perfect Vision develops and manufactures femtosecond laser equipment for refractive eye surgery. Remained on the Board until leaving Innoven in June 2007.

Invested in and became Director of a biotech company focused on the treatment of peripheral and central nervous system disorders.Raised two private rounds and established commercial partnerships to co-develop the company's lead product, targeting the neuropathic pain, diabetic neuropathy, traumatic brain injury and Alzheimers markets.Remained as Director following my resignation to focus on the acquisition of Innoven Partenaires.

Co-founded the company to develop a regulated market for investing in private growth companies and act as a feeder exchange to the major European stock exchanges. Also developed a software platform for managing R&D activities.Raised two rounds of finance.

Built up the M&A advisory activities of this specialized healthcare consultancy over a 6 year period, developing a leading position in the contract drug development sector. Worked with private European and Nasdaq listed life science service organizations on cross-border M&A deals.Acted as the sole adviser on a three-way merger between a US-based company, Kendle, and two European companies in order to allow Kendle to complete and IPO on Nasdaq in 1997. Kendle became Business Week's "Hottest Growth Company" in 1998. I subsequently advised Kendle on several follow-on acquisitions in a roll-up strategy with targets across Europe and in Australia leading to >20x increase in revenues over a 4 year period as advisor.Assisted in the raising of Technomark Medical Ventures, a £25M venture capital fund focused on medical sciences, introducing one of its first investments (BioVex).

Cross-border M&A, particularly in the pharmaceutical sector.Also worked on oil and gas, capital goods and telecom industry mergers and fairness opinions across Europe, including advising acquirors on the purchase of two companies sold during the Italian government's privatisation programme.